Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone
dc.contributor.author | Clarke, Noel W | |
dc.contributor.author | Thiery-Vuillemin, A | |
dc.contributor.author | Wiechno, PJ | |
dc.contributor.author | Alekseev, B | |
dc.contributor.author | Sala, N | |
dc.contributor.author | Jones, R | |
dc.contributor.author | Kocak, I | |
dc.contributor.author | Chiuri, VE | |
dc.contributor.author | Jassem, J | |
dc.contributor.author | Flechon, A | |
dc.contributor.author | Redfern, C | |
dc.contributor.author | Goessl, CD | |
dc.contributor.author | Burgents, J | |
dc.contributor.author | Gresty, C | |
dc.contributor.author | Degboe, A | |
dc.contributor.author | Saad, F | |
dc.date.accessioned | 2019-11-19T16:01:09Z | |
dc.date.available | 2019-11-19T16:01:09Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Clarke NW, Thiery-Vuillemin A, Wiechno PJ, Alekseev B, Sala N, Jones R, et al. Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone. J Clin Oncol. 2019;37(7_suppl):234-. | en |
dc.identifier.doi | 10.1200/JCO.2019.37.7_suppl.234 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622473 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1200/JCO.2019.37.7_suppl.234 | en |
dc.title | Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | The Christie and Salford Royal Hospitals, Manchester | en |
dc.identifier.journal | Journal of Clinical Oncology | en |